These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3539323)

  • 41. Toxicity of a monoclonal F(ab')2:ricin A conjugate for retinoblastoma in vitro.
    Merriam JC; Lyon HS; Char DH
    Cancer Res; 1984 Aug; 44(8):3178-83. PubMed ID: 6744258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific killing of mouse leukemic cells with ricin A-chain immunotoxin.
    Wiedłocha A; Salwa J; Paprocka M; Steuden I; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1989; 37(1-2):101-13. PubMed ID: 2619494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
    Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
    Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mice are actively immunized after passive monoclonal antibody prophylaxis and ricin toxin challenge.
    Lemley PV; Wright DC
    Immunology; 1992 Jul; 76(3):511-3. PubMed ID: 1526657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytotoxicity of streptavidin-blocked biotinyl-ricin is retrieved by in vitro immunotargeting via biotinyl monoclonal antibody.
    Schechter B; Arnon R; Wilchek M
    Cancer Res; 1992 Aug; 52(16):4448-52. PubMed ID: 1643636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of ricin B chain on the intracellular trafficking of an A chain immunotoxin.
    Timar J; McIntosh DP; Henry R; Cumber AJ; Parnell GD; Davies AJ
    Br J Cancer; 1991 Oct; 64(4):655-62. PubMed ID: 1911213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.
    Killen JA; Lindstrom JM
    J Immunol; 1984 Nov; 133(5):2549-53. PubMed ID: 6332854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents.
    Byers VS; Pimm MV; Pawluczyk IZ; Lee HM; Scannon PJ; Baldwin RW
    Cancer Res; 1987 Oct; 47(20):5277-83. PubMed ID: 3498532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Present potential of immunotoxins.
    Poncelet P; Blythman HE; Carriere D; Casellas P; Dussossoy D; Gros O; Gros P; Jansen FK; Laurent JC; Liance MC
    Behring Inst Mitt; 1984 May; (74):94-100. PubMed ID: 6383330
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mouse multivalent IgG(2a, b) antibody--ricin A-chain immunotoxins combined with homologous or heterologous interleukin 2 in the treatment of a murine malignant lymphoproliferation (EL4).
    Mota G; Marches R; Cialacu V; Roman V; Kozma E; Mărgineanu M; Dima S; Moraru II
    Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):131-6. PubMed ID: 8915518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
    Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
    Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective cytotoxicity of a ricin A-chain-anti-carcinoembryonic antigen antibody conjugate for a human colon adenocarcinoma cell line.
    Griffin TW; Haynes LR; DeMartino JA
    J Natl Cancer Inst; 1982 Oct; 69(4):799-805. PubMed ID: 6956757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro.
    Canevari S; Orlandi R; Ripamonti M; Tagliabue E; Aguanno S; Miotti S; Menard S; Colnaghi MI
    J Natl Cancer Inst; 1985 Nov; 75(5):831-9. PubMed ID: 3863986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravesical immunotoxin as adjuvant therapy to prevent the recurrence of bladder cancer.
    Zang Z; Xu H; Yu L; Yang D; Xie S; Shi Y; Li Z; Li J; Wang J; Li M; Guo Y; Gu F
    Chin Med J (Engl); 2000 Nov; 113(11):1002-6. PubMed ID: 11776112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intratumour therapy of solid tumours with ricin-antibody conjugates.
    Kanellos J; McKenzie IF; Pietersz GA
    Immunol Cell Biol; 1989 Apr; 67 ( Pt 2)():89-99. PubMed ID: 2786496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.